Email this article Microenvironment-related predictive markers of the therapeutic effectiveness of eribulin in patients with locally advanced or metastatic breast cancer: pilot study
- Authors: Tashireva L.A.1, Popova N.O.1, Alifanov V.V.1, Goldberg V.E.1, Kovalenko E.I.2,3, Artamonova E.V.2, Manikhas A.G.4, Ponomarenko D.M.5,6, Levchenko N.V.7, Rossokha E.I.8, Krasilnikova S.Y.9, Zafirova M.A.10, Perelmuter V.M.1
-
Affiliations:
- Research Institute of Oncology, Tomsk National Research Medical Center of the Russian Academy of Sciences
- N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia
- Department of Surgical Oncology No. 1, Saint Petersburg Clinical Oncology Dispensary
- Irkutsk Regional Oncology Dispensary
- Irkutsk State Medical Academy of Postgraduate Education, a branch of Russian Medical Academy of Postgraduate Education, Ministry of Health of Russia
- Saint Petersburg Clinical Research and Practical Center for Specialized Medical Care (Oncological), Ministry of Health of Russia
- Altai Regional Oncology Dispensary
- Sverdlovsk Regional Oncology Dispensary
- Ural State Medical University, Ministry of Health of Russia
- Issue: Vol 17, No 4 (2021)
- Pages: 48-55
- Section: MAMMOLOGY. ORIGINAL REPORTS
- Published: 20.12.2021
- URL: https://ojrs.abvpress.ru/ojrs/article/view/895
- DOI: https://doi.org/10.17650/1994-4098-2021-17-4-48-55
- ID: 895
Cite item
Full Text
Abstract
Background. Triple negative breast cancer has no specific treatment sites for chemotherapy and is unfavorable in terms of prognosis. One of the drugs widely used in this cohort of patients is eribulin, which in addition to its antimitotic effect has an effect on the tumor microenvironment. The search for biological criteria that will allow predicting the effectiveness of the drug is assumed relevant since it will help to select patients who may receive the most benefit from certain therapy regimens.
Objective: identification of immunological predictors of the therapeutic effectiveness of eribulin in patients with locally advanced or metastatic triple-negative breast cancer.
Materials and methods. The study included 20 patients with locally advanced and metastatic triple negative breast cancer. 50 % had a short-term response (progression-free survival <3 months) to eribulin therapy, and 50 % had a long-term response (progression-free survival >6 months). Seven-color immunofluorescence was used to determine the subpopulation composition of tumor-infiltrating lymphocytes and their PD1 expression. Image acquisition and analysis were performed using the Vectra® 3.0 system and InForm® software (Akoya Biosciences, USA).
Results. It has been shown that the ratio of the number of PD1-negative to PD1-positive CD20+ B-lymphocytes less than 5.5 associated with the long-term effectiveness of eribulin in patients with locally advanced or metastatic triple negative breast cancer.
Conclusion. The results showed that the ratio of the number of PD1-negative to PD1-positive CD20+ B-lymphocytes can be considered as a possible marker to predict the effectiveness of eribulin in patients with breast cancer.
Keywords
About the authors
L. A. Tashireva
Research Institute of Oncology, Tomsk National Research Medical Center of the Russian Academy of Sciences
Author for correspondence.
Email: lkleptsova@mail.ru
Lyubov Aleksandrovna Tashireva.
5 Kooperativnyy Per., Tomsk 634009.
Russian FederationN. O. Popova
Research Institute of Oncology, Tomsk National Research Medical Center of the Russian Academy of Sciences
5 Kooperativnyy Per., Tomsk 634009.
Russian FederationV. V. Alifanov
Research Institute of Oncology, Tomsk National Research Medical Center of the Russian Academy of Sciences
5 Kooperativnyy Per., Tomsk 634009.
Russian FederationV. E. Goldberg
Research Institute of Oncology, Tomsk National Research Medical Center of the Russian Academy of Sciences
5 Kooperativnyy Per., Tomsk 634009.
Russian FederationE. I. Kovalenko
N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia;
24 Kashirskoe Shosse, Moscow 115478.
Russian FederationE. V. Artamonova
N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia
24 Kashirskoe Shosse, Moscow 115478.
Russian FederationA. G. Manikhas
Department of Surgical Oncology No. 1, Saint Petersburg Clinical Oncology Dispensary
56 Prospekt Veteranov, Saint Petersburg 198255.
Russian FederationD. M. Ponomarenko
Irkutsk Regional Oncology Dispensary; Irkutsk State Medical Academy of Postgraduate Education, a branch of Russian Medical Academy of Postgraduate Education, Ministry of Health of Russia
1 Studencheskaya St., Bratsk 665709; 100k 4 Yubileynyy District, Irkutsk 664049.
Russian FederationN. V. Levchenko
Saint Petersburg Clinical Research and Practical Center for Specialized Medical Care (Oncological), Ministry of Health of Russia
68A Leningradskaya St., Pesochnyy Settlement, Saint Petersburg 197758.
Russian FederationE. I. Rossokha
Altai Regional Oncology Dispensary
50 Sotsialisticheskiy Prospekt, Barnaul 656044.
Russian FederationS. Yu. Krasilnikova
Sverdlovsk Regional Oncology Dispensary
11 Komsomolskaya St., Ekaterinburg 620137.
Russian FederationM. A. Zafirova
Ural State Medical University, Ministry of Health of Russia
3 Studencheskaya St., Ekaterinburg 620028.
Russian FederationV. M. Perelmuter
Research Institute of Oncology, Tomsk National Research Medical Center of the Russian Academy of Sciences
5 Kooperativnyy Per., Tomsk 634009.
Russian FederationReferences
- Kuznetsov G., Towle M.J., Cheng H. et al. Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389. Cancer Res 2004;64(16):5760–6.
- Jordan M.A., Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004;4(4):253–65.
- Hüsemann L.C., Reese A., Radine C. et al. The microtubule targeting agents eribulin and paclitaxel activate similar signaling pathways and induce cell death predominantly in a caspase-independent manner. Cell Cycle 2020;19(4):464–78. doi: 10.1080/15384101.2020.1716144.
- Yoshida T., Ozawa Y., Kimura T. et al. Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states. J Br J Cancer 2014;110(6):1497–505.
- Funahashi Y., Okamoto K., Adachi Y. et al. Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models. Cancer Sci 2014;105(10):1334–42. doi: 10.1111/cas.12488.
- Kashiwagi S., Asano Y., Goto W. et al. Use of tumor-infiltrating lymphocytes (TILs) to predict the treatment response to eribulin chemotherapy in breast cancer. PLoS One 2017;12(2):e0170634. doi: 10.1371/journal.pone.0170634.
- Goto W., Kashiwagi S., Asano Y. et al. Eribulin promotes antitumor immune responses in patients with locally advanced or metastatic breast cancer. Anticancer Res 2018;38(5):2929–38.
- Dieci M.V., Radosevic-Robin N., Fineberg S. et al. International ImmunoOncology Biomarker Working Group on Breast Cancer. Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. Semin Cancer Biol 2018;52(Pt 2):16–25. doi: 10.1016/j.semcancer.2017.10.003.
- Gao G., Wang Z., Qu X., Zhang Z. Prognostic value of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer: a systematic review and meta-analysis. BMC Cancer 2020;20(1):179. doi: 10.1186/s12885-020-6668-z.
- Brockhoff G., Seitz S., Weber F. et al. The presence of PD-1 positive tumor infiltrating lymphocytes in triple negative breast cancers is associated with a favorable outcome of disease. Oncotarget 2017;9(5):6201–12. doi: 10.18632/oncotarget.23717.
Supplementary files
